...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: 6%

In the AGM presentation (no longer available), on slide 14, bottom right, it says (under Zenith Epigenetics Ltd.) -- "6% Royalty to be paid to Zenith Capital Corp."

Either I don't know or have just forgotten what that refers to.  Any thoughts?

I'm a bit wary of the company structure.  As I recall DM said they created Zenith Epigenetics (ZE) so 3694 could be sold, while keeping everything else in ZCC.  Me?  I wonder if they created ZE to limit what gets distributed to ZCC and to shareholders.

 

 

Share
New Message
Please login to post a reply